Vivos Therapeutics

VVOS

Market cap $5.83M

VVOS Hedge Fund Activity: Q1 2026 in Review

24 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q1 2026, worth a combined $2.15M — up 61% from $1.34M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new VVOS positions and 2 closed out — a net gain of 6 holders — while 3 added to existing stakes and 2 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $1.79M. The largest seller was DRW Securities, exiting entirely with an estimated $235K sold.

• 24 institutional investors held Vivos Therapeutics (VVOS) as of Q1 2026, up from 19 in Q4 2025.
• Funds reported $2.15M of Vivos Therapeutics stock for Q1 2026, up 61% quarter-over-quarter.
• 8 funds opened new Vivos Therapeutics positions in Q1 2026 and 2 closed out, a net change of +6 holders.
• The largest Vivos Therapeutics buyer in Q1 2026 was Armistice Capital, an estimated $1.79M added.
• The largest Vivos Therapeutics seller in Q1 2026 was DRW Securities, an estimated $235K sold.

Based on aggregated 13F filings for Q1 2026.